Case report: Low circulating IGF-I levels due to Acid-Labile Subunit deficiency in adulthood are not associated with early development of atherosclerosis and impaired heart function

Growth Hormone and IGF Research

Volumn 21, Issue 4, 2011, Pages 233-237

  Rensing, K L ^a   van Duyvenvoorde, H A ^b   Cramer, M J ^c   Teske, A J ^c   Prokop, M ^d   Stroes, E S ^a   Wit, J M ^b   Hermus, A R M M ^d   Twickler, T H B ^a,e  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Lievensberg Hospital   (Netherlands)

Author keywords

Acid Labile Subunit deficiency; Cardiovascular disease; Insulin like growth factor I

Indexed keywords

ACID LABILE SUBUNIT; PROTEIN SUBUNIT; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ACID LABILE SUBUNIT GENE; ADULT; ARTICLE; ATHEROGENESIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; ECHOCARDIOGRAPHY; FRAMINGHAM RISK SCORE; GENE; GENE MUTATION; GENETIC ASSOCIATION; HEART DISEASE; HEART PERFORMANCE; HUMAN; MALE; ONSET AGE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; THREE DIMENSIONAL IMAGING;

ADULT; ATHEROSCLEROSIS; CARRIER PROTEINS; GLYCOPROTEINS; HEART FAILURE; HOMOZYGOTE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MUTATION;

EID: 79960438957     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2011.05.004     Document Type: Article

References (28)

1. Fofanova-Gambetti O.V., Hwa V., Wit J.M., et al. Impact of heterozygosity for acid-labile subunit (IGFALS) gene mutations on stature: results from the international acid-labile subunit consortium. J. Clin. Endocrinol. Metab. 2010, 95:4184-4191.
2. Laughlin G.A., Barrett-Connor E., Criqui M.H., Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J. Clin. Endocrinol. Metab. 2004, 89:114-120.
3. Juul A., Scheike T., Davidsen M., Gyllenborg J., Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 2002, 106:939-944.
4. Friedrich N., Haring R., Nauck M., et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J. Clin. Endocrinol. Metab. 2009, 94:1732-1739.
5. Vasan R.S., Sullivan L.M., D'Agostino R.B., et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann. Intern. Med. 2003, 139:642-648.
6. Jankowska E.A., Biel B., Majda J., et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006, 114:1829-1837.
7. Hassfeld S., Eichhorn C., Stehr K., et al. Insulin-like growth factor-binding proteins 2 and 3 are independent predictors of a poor prognosis in patients with dilated cardiomyopathy. Heart 2007, 93:359-360.
8. Colao A. The GH/IGF axis and the cardiovascular system: clinical implications. Clin. Endocrinol. (Oxf) 2008, 69:347-358.
9. van Duyvenvoorde H.A., Kempers M.J., Twickler T.B., et al. Homozygous and heterozygous expression of a novel mutation of the acid-labile subunit. Eur. J. Endocrinol. 2008, 159:113-120.
10. Meijboom W.B., Meijs M.F., Schuijf J.D., et al. Diagnostic accuracy of 64-slice computed tomography coronary angiography: a prospective, multicenter, multivendor study. J. Am. Coll. Cardiol. 2008, 52:2135-2144.
11. Meijs M.F., Meijboom W.B., Bots M.L., et al. Comparison of frequency of calcified versus non-calcified coronary lesions by computed tomographic angiography in patients with stable versus unstable angina pectoris. Am. J. Cardiol. 2009, 104:305-311.
12. Teske A.J., De Boeck B.W., Melman P.G., Sieswerda G.T., Doevendans P.A., Cramer M.J. Echocardiographic quantification of myocardial function using tissue deformation imaging, a guide to image acquisition and analysis using tissue Doppler and speckle tracking. Cardiovasc. Ultrasound. 2007, 5:27.
13. DuBois D., DuBois E. A formula to estimate the approximate surface area if height and weight be known. Arch. Intern. Med. 1916, 17:863-871.
14. Domene H.M., Hwa V., Argente J., et al. Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences. Horm. Res. 2009, 72:129-141.
15. Kaplan R.C., McGinn A.P., Pollak M.N., et al. Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J. Clin. Endocrinol. Metab. 2007, 92:1319-1325.
16. Page J.H., Ma J., Pollak M., Manson J.E., Hankinson S.E. Plasma insulin-like growth factor 1 and binding-protein 3 and risk of myocardial infarction in women: a prospective study. Clin. Chem. 2008, 54:1682-1688.
17. Lawlor D.A., Ebrahim S., Smith G.D., Cherry L., Watt P., Sattar N. The association of insulin-like-growth factor 1 (IGF-1) with incident coronary heart disease in women: findings from the prospective British Women's Heart and Health Study. Atherosclerosis 2008, 201:198-204.
18. Andreassen M., Raymond I., Kistorp C., Hildebrandt P., Faber J., Kristensen L.O. IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur. J. Endocrinol. 2009, 160:25-31.
19. Saydah S., Graubard B., Ballard-Barbash R., Berrigan D. Insulin-like growth factors and subsequent risk of mortality in the United States. Am. J. Epidemiol. 2007, 166:518-526.
20. Andreassen M., Kistorp C., Raymond I., et al. Plasma insulin-like growth factor I as predictor of progression and all cause mortality in chronic heart failure. Growth Horm. IGF. Res. 2009, 19:486-490.
21. van der Klaauw A.A., Biermasz N.R., Feskens E.J., et al. The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. Eur. J. Endocrinol. 2007, 156:455-462.
22. Filipsson H., Monson J.P., Koltowska-Haggstrom M., Mattsson A., Johannsson G. The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J. Clin. Endocrinol. Metab. 2006, 91:3954-3961.
23. Yamaguchi H., Komamura K., Choraku M., et al. Impact of serum insulin-like growth factor-1 on early prognosis in acute myocardial infarction. Intern. Med. 2008, 47:819-825.
24. Yazdanpanah M., Sayed-Tabatabaei F.A., Janssen J.A., et al. IGF-I gene promoter polymorphism is a predictor of survival after myocardial infarction in patients with type 2 diabetes. Eur. J. Endocrinol. 2006, 155:751-756.
25. Li Q., Li B., Wang X., et al. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J. Clin. Invest. 1997, 100:1991-1999.
26. Davis M.E., Hsieh P.C., Takahashi T., et al. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:8155-8160.
27. Kotlyar A.A., Vered Z., Goldberg I., et al. Insulin-like growth factor I and II preserve myocardial structure in postinfarct swine. Heart 2001, 86:693-700.
28. Poutanen T., Jokinen E., Sairanen H., Tikanoja T. Left atrial and left ventricular function in healthy children and young adults assessed by three dimensional echocardiography. Heart 2003, 89:544-549.